what is the matter with this stock?

QRX Pharma today announced that it had submitted its NDA to the FDA. They indicated that it will take 10-12 months to gain approval. The company is seeking a licencing partner for some or all of the Moxduo product range across soem or all global markets. We are talking about a multi billion dollar market. Brokers have a target price of circa $3.00 on the shares.

The stock FELL on this news.

What can anyone tell me about the difficulty of selling into the pain market and/or the unliklihood of getting a decent up from licence fee. I had been expecting an up-front payment in the "tens of millions" PLUS milestones for FDA approval PLUS sales benchmarks PLUS royalties.....

Current market cap of circa $200m does not seem to reflect the real upsid epotential unless.......

To me, the story is hardly complex and its its FDA application is not seen as a "risk" since both of the component compounds for Moxduo are already proven to be safe and efficatious (if that is th eirght spelling).

Where are the instos and why are they shy of this stock?

All clues appreciated.

I hold the stock.

DYOR